Aug 20, 2026 08:00AM
Aug 12, 2026 07:30AM
Jul 14, 2026 06:44AM
May 12, 2026 08:30AM
Apr 17, 2026 04:01PM
Apr 17, 2026 04:01PM
Apr 14, 2026 07:01AM Adagene adds Peter Lebowitz to scientific advisory board
Apr 14, 2026 07:00AM
Apr 7, 2026 07:49AM
Apr 2, 2026 07:01AM
Apr 2, 2026 07:01AM
Apr 2, 2026 07:00AM
Apr 2, 2026 07:00AM
Apr 1, 2026 05:00PM Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Mar 17, 2026 04:35PM
Mar 10, 2026 05:31PM
Feb 17, 2026 09:27AM
Jan 23, 2026 08:00AM
Dec 16, 2025 07:00AM
Dec 16, 2025 07:00AM
Oct 31, 2025 07:00AM Adagene doses first patient in phase 2 colorectal cancer study
Oct 31, 2025 07:00AM
Sep 3, 2025 09:05AM
Sep 3, 2025 09:05AM
Aug 15, 2025 06:53AM
Aug 12, 2025 04:05PM
Jul 15, 2025 07:01AM
Jul 15, 2025 07:00AM Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
Mar 24, 2025 08:00AM
Sep 16, 2024 03:01AM
Feb 9, 2024 06:01AM
Feb 9, 2024 06:00AM
Jan 9, 2023 07:02AM
Jan 9, 2023 07:00AM
Jan 9, 2023 07:00AM Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose
Dec 16, 2022 06:32AM
Dec 16, 2022 06:30AM
Dec 16, 2022 06:30AM
Mar 31, 2022 08:30AM
Mar 31, 2022 08:30AM
Mar 16, 2022 07:00AM
Mar 16, 2022 07:00AM Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Feb 2, 2022 04:23PM
Feb 2, 2022 04:05PM
Nov 30, 2021 09:28AM
Nov 29, 2021 06:03PM
Nov 29, 2021 04:06PM
Nov 29, 2021 04:05PM
Aug 26, 2021 07:45AM Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
Aug 26, 2021 07:45AM

329,911 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All